Novo Nordisk (NVO) closed the most recent trading day at $47.81, moving -2.35% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%. Meanwhile, the ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Pfizer revised its revenue expectations for 2025 and detailed its outlook for 2026. Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in ...